Developer docs
API playgroundTry for free, no card

Search company profiles

Actithera

Full company profile

uuid0000bma

Namestring
Actithera
Legal namestring
Actithera, Inc.
Websiteurl
actithera.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Actithera is a discovery-stage radiopharmaceutical biotech founded in 2021 that develops next-generation radioligand therapies (RLTs) for cancer. The company targets oncology patients with high unmet medical needs, focusing on tumors that express fibroblast activation protein (FAP) and other cancer-associated targets where conventional chemotherapy and external beam radiation lack sufficient precision. Actithera operates dual headquarters in Cambridge, Massachusetts (US corporate) and Oslo, Norway (R&D), with a small team of 1–10 employees concentrated in radiochemistry, in vivo pharmacology, cell biology, and preclinical imaging.

The company's core technology is a proprietary chemistry platform that combines covalent binding chemistry with an isotope-agnostic design. Covalent ligands form irreversible bonds with tumor-associated proteins, prolonging tumor residence time and enabling more efficient radiation delivery while sparing healthy tissues. The platform is flexible across alpha emitters (²²⁵Ac) and beta emitters (¹⁷⁷Lu, ¹⁶¹Tb), allowing isotope selection based on biological rationale rather than chemistry constraints. The lead asset is a FAP-targeting small molecule RLT currently in IND-enabling studies, supplemented by undisclosed small molecule and peptide pipeline programs. The chemistry platform is reinforced by an exclusive license from Yeda (Weizmann Institute of Science) to two patent families developed in Professor Nir London's laboratory covering site-specific, durable, and traceless radiolabeling.

As a pre-commercial biotech, Actithera does not currently generate product revenue. The intended business model combines pharmaceutical commercialization of approved RLTs through hospital and specialty oncology channels with potential platform licensing to pharmaceutical partners. The $75.5 million Series A financing closed in July 2025 is funding clinical development of the lead FAP asset and expansion of the discovery platform.

Short descriptiontext

Actithera is a discovery-stage radiopharmaceutical biotech developing covalent, isotope-agnostic radioligand therapies for cancer, with a lead FAP-targeting small molecule in IND-enabling studies and operations in Cambridge, MA and Oslo.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radioligand therapy, radiopharmaceutical development, precision oncology, covalent drug chemistry, targeted cancer therapeutics
Industry2 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Radiopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Radiopharmaceutical Development and Commercialization
TypeOne Time License
Description

Pre-commercial biotech company developing a pipeline of radioligand therapies. Revenue model will likely follow traditional pharmaceutical commercialization through prescription-based sales, targeting hospital and specialty oncology clinic channels upon regulatory approval.

arcticstartup.com
2Platform Licensing and Partnerships
TypeLicensing Royalties
Description

The company may pursue licensing agreements for its proprietary chemistry platform technologies and discovery engine capabilities to pharmaceutical partners.

actithera.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Actithera is a discovery-stage radiopharmaceutical biotech that develops next-generation radioligand therapies (RLTs) by linking radioactive isotopes to proprietary small molecule and peptide ligands. Its lead asset is a FAP-targeting small molecule radioligand therapy in IND-enabling studies, supported by a covalent chemistry platform that prolongs tumor retention and is isotope-agnostic across alpha and beta emitters.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More efficient and sustained radiation delivery to tumors through prolonged tumor retention
+2 more records
Product overview1 text field

Actithera is a discovery-stage radiopharmaceutical biotech company with a proprietary chemistry platform for developing next-generation radioligand therapies (RLTs). The core portfolio includes a lead FAP-targeting small molecule radioligand therapy currently in IND-enabling studies, supported by an exclusive license to Weizmann Institute's covalent chemistry technologies. The platform is isotope-agnostic, enabling use of alpha or beta emitters (¹⁷⁷Lu, ²²⁵Ac, ¹⁶¹Tb), and supports a pipeline of undisclosed small molecule and peptide programs across discovery and preclinical stages.

Product and service3 records
1FAP-Targeting Radioligand Therapy
CategoryRadioligand Therapy (lead product)
Description

Lead small molecule radiopharmaceutical therapy developed by Actithera targeting fibroblast activation protein (FAP). Designed to persist in tumors while sparing healthy tissues through proprietary covalent chemistry; currently in IND-enabling studies for cancer patients.

2Radioligand Therapy Platform
CategoryDiscovery & Development Platform
Description

Proprietary chemistry platform for discovering and developing next-generation radioligand therapies with superior tumor retention, isotope-agnostic design, and applicability across diverse cancer targets including small molecules and peptides.

3Undisclosed Pipeline Programs
CategoryPipeline assets
Description

Pipeline of undisclosed small molecule and peptide-based radioligand therapies targeting various cancer indications, at different discovery and preclinical stages.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-14
Description

Exclusive license agreement for two patent families covering covalent chemistry technologies developed in Professor Nir London's laboratory. These technologies enable site-specific, durable, and traceless radiolabeling of tumor-specific proteins, designed to enhance tumor selectivity and retention in radiopharmaceuticals for cancer treatment. Integration into Actithera's existing discovery platform supports next-generation RLT design across oncology indications.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novartis commercializes Pluvicto (177Lu-PSMA-617) and Lutathera, the dominant approved radioligand therapies that define the market Actithera is targeting. Actithera's CMO Dr. Dalal previously led radioligand development at Novartis, making it both the gold-standard incumbent and a likely future acquirer/partner.

TypeBroad incumbent
Description

Bayer operates Xofigo (Ra-223) and is actively investing in next-generation radiopharmaceuticals through its pharma division. Bayer has been an aggressive acquirer of radiopharma assets and represents a major strategic competitor and potential acquirer.

TypeBroad incumbent
Description

Lantheus is a specialized radiopharmaceutical company with commercial products including Pylarify (Pyl-PSMA, a PSMA PET imaging agent). Lantheus's theranostic focus and commercial radiopharma infrastructure make it a direct comparable in the diagnostic+therapeutic radiopharmaceutical space.

TypeBroad incumbent
Description

Telix is a commercial-stage radiopharmaceutical company with multiple approved imaging agents and an expanding therapeutic pipeline. Its PSMA imaging franchise and growing RLT pipeline make it a key direct competitor for both diagnostic and therapeutic market share.

TypeDirect peer
Description

ITM is a therapeutic radiopharmaceutical biotech developing targeted radionuclide therapies, with proprietary177Lu production capabilities. ITM's pipeline of oncology RLTs and isotope supply positioning make it a direct comparable in therapeutic radiopharmaceutical development.

6Philochips
TypeDirect peer
Description

Philochips is an emerging RLT biotech pursuing FAP-targeting radioligand therapies—the same target as Actithera's lead asset. Direct head-to-head competition on FAP, a validated oncology target, makes Philochips the closest direct peer on the lead program.

TypeDirect peer
Description

Mariana Oncology was a radioligand therapy platform company with a diversified pipeline across multiple targets and radionuclides—recently acquired by GSK for up to $1.7B. Mariana's platform model and similar stage pre-acquisition make it a highly comparable peer, demonstrating pharma appetite for radiopharma platforms.

TypeDirect peer
Description

RayzeBio developed actinium-225-based radiopharmaceuticals and was acquired by Bristol-Myers Squibb for $4.1B in 2024. RayzeBio's alpha-emitter focus and similar pre-commercial stage profile make it a benchmark comparable for both platform value and likely acquisition outcomes.

TypeDirect peer
Description

Fusion Pharmaceuticals developed targeted alpha therapies (TAT) using actinium-225 and was acquired by AstraZeneca for $2.4B in 2024. Fusion's alpha-emitter radiopharma platform and oncology focus directly parallel Actithera's isotope-agnostic, covalent-chemistry approach.

TypeDirect peer
Description

Ariceum is an emerging radiopharmaceutical biotech developing RLTs for cancer with a focus on targets including somatostatin receptors and other oncology indications. As a private, clinical-stage RLT biotech, Ariceum offers a close comparable for Actithera's development trajectory and fundraising profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Actithera

Radiopharmaceuticalsactithera.com

Actithera is a discovery-stage radiopharmaceutical biotech developing covalent, isotope-agnostic radioligand therapies for cancer, with a lead FAP-targeting small molecule in IND-enabling studies and operations in Cambridge, MA and Oslo.

What Actithera does

Actithera is a discovery-stage radiopharmaceutical biotech founded in 2021 that develops next-generation radioligand therapies (RLTs) for cancer. The company targets oncology patients with high unmet medical needs, focusing on tumors that express fibroblast activation protein (FAP) and other cancer-associated targets where conventional chemotherapy and external beam radiation lack sufficient precision. Actithera operates dual headquarters in Cambridge, Massachusetts (US corporate) and Oslo, Norway (R&D), with a small team of 1–10 employees concentrated in radiochemistry, in vivo pharmacology, cell biology, and preclinical imaging.

The company's core technology is a proprietary chemistry platform that combines covalent binding chemistry with an isotope-agnostic design. Covalent ligands form irreversible bonds with tumor-associated proteins, prolonging tumor residence time and enabling more efficient radiation delivery while sparing healthy tissues. The platform is flexible across alpha emitters (²²⁵Ac) and beta emitters (¹⁷⁷Lu, ¹⁶¹Tb), allowing isotope selection based on biological rationale rather than chemistry constraints. The lead asset is a FAP-targeting small molecule RLT currently in IND-enabling studies, supplemented by undisclosed small molecule and peptide pipeline programs. The chemistry platform is reinforced by an exclusive license from Yeda (Weizmann Institute of Science) to two patent families developed in Professor Nir London's laboratory covering site-specific, durable, and traceless radiolabeling.

As a pre-commercial biotech, Actithera does not currently generate product revenue. The intended business model combines pharmaceutical commercialization of approved RLTs through hospital and specialty oncology channels with potential platform licensing to pharmaceutical partners. The $75.5 million Series A financing closed in July 2025 is funding clinical development of the lead FAP asset and expansion of the discovery platform.

Actithera firmographics

Firmographics
Name
Actithera
Legal name
Actithera, Inc.
Website
https://actithera.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Actithera is a discovery-stage radiopharmaceutical biotech developing covalent, isotope-agnostic radioligand therapies for cancer, with a lead FAP-targeting small molecule in IND-enabling studies and operations in Cambridge, MA and Oslo.
Ownership category
akta.pro rank

Actithera industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Radioligand therapy
  • Radiopharmaceutical development
  • Precision oncology
  • Covalent drug chemistry
  • Targeted cancer therapeutics

Where Actithera is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Actithera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Radiopharmaceutical Development and Commercialization: Pre-commercial biotech company developing a pipeline of radioligand therapies. Revenue model will likely follow traditional pharmaceutical commercialization through prescription-based sales, targeting hospital and specialty oncology clinic channels upon regulatory approval.
  2. Platform Licensing and Partnerships: The company may pursue licensing agreements for its proprietary chemistry platform technologies and discovery engine capabilities to pharmaceutical partners.

Go-to-market motion1 record

Marketing channels4 records

Actithera product offering

Product offering

Core offering

Actithera is a discovery-stage radiopharmaceutical biotech that develops next-generation radioligand therapies (RLTs) by linking radioactive isotopes to proprietary small molecule and peptide ligands. Its lead asset is a FAP-targeting small molecule radioligand therapy in IND-enabling studies, supported by a covalent chemistry platform that prolongs tumor retention and is isotope-agnostic across alpha and beta emitters.

Product overview

Actithera is a discovery-stage radiopharmaceutical biotech company with a proprietary chemistry platform for developing next-generation radioligand therapies (RLTs). The core portfolio includes a lead FAP-targeting small molecule radioligand therapy currently in IND-enabling studies, supported by an exclusive license to Weizmann Institute's covalent chemistry technologies. The platform is isotope-agnostic, enabling use of alpha or beta emitters (¹⁷⁷Lu, ²²⁵Ac, ¹⁶¹Tb), and supports a pipeline of undisclosed small molecule and peptide programs across discovery and preclinical stages.

Differentiator

Problem solved

Functional benefit

Products and services

  • FAP-Targeting Radioligand Therapy Lead small molecule radiopharmaceutical therapy developed by Actithera targeting fibroblast activation protein (FAP). Designed to persist in tumors while sparing healthy tissues through proprietary covalent chemistry; currently in IND-enabling studies for cancer patients.
  • Radioligand Therapy Platform Proprietary chemistry platform for discovering and developing next-generation radioligand therapies with superior tumor retention, isotope-agnostic design, and applicability across diverse cancer targets including small molecules and peptides.
  • Undisclosed Pipeline Programs Pipeline of undisclosed small molecule and peptide-based radioligand therapies targeting various cancer indications, at different discovery and preclinical stages.

Quantifiable outcome

  • More efficient and sustained radiation delivery to tumors through prolonged tumor retention
  • +2 more outcomes

Companies that use Actithera

Customer profile

Segments1 record

Ideal customer profiles2 records

Actithera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Actithera partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Yeda / Weizmann Institute of SciencecoreTechnology or Integration · 14 October 2025Exclusive license agreement for two patent families covering covalent chemistry technologies developed in Professor Nir London's laboratory. These technologies enable site-specific, durable, and traceless radiolabeling of tumor-specific proteins, designed to enhance tumor selectivity and retention in radiopharmaceuticals for cancer treatment. Integration into Actithera's existing discovery platform supports next-generation RLT design across oncology indications.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Actithera competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Novartis commercializes Pluvicto (177Lu-PSMA-617) and Lutathera, the dominant approved radioligand therapies that define the market Actithera is targeting. Actithera's CMO Dr. Dalal previously led radioligand development at Novartis, making it both the gold-standard incumbent and a likely future acquirer/partner.
  • Bayer: Bayer operates Xofigo (Ra-223) and is actively investing in next-generation radiopharmaceuticals through its pharma division. Bayer has been an aggressive acquirer of radiopharma assets and represents a major strategic competitor and potential acquirer.
  • Lantheus Holdings: Lantheus is a specialized radiopharmaceutical company with commercial products including Pylarify (Pyl-PSMA, a PSMA PET imaging agent). Lantheus's theranostic focus and commercial radiopharma infrastructure make it a direct comparable in the diagnostic+therapeutic radiopharmaceutical space.
  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with multiple approved imaging agents and an expanding therapeutic pipeline. Its PSMA imaging franchise and growing RLT pipeline make it a key direct competitor for both diagnostic and therapeutic market share.

Direct peers

  • ITM Isotope Technologies: ITM is a therapeutic radiopharmaceutical biotech developing targeted radionuclide therapies, with proprietary177Lu production capabilities. ITM's pipeline of oncology RLTs and isotope supply positioning make it a direct comparable in therapeutic radiopharmaceutical development.
  • Philochips: Philochips is an emerging RLT biotech pursuing FAP-targeting radioligand therapies—the same target as Actithera's lead asset. Direct head-to-head competition on FAP, a validated oncology target, makes Philochips the closest direct peer on the lead program.
  • Mariana Oncology: Mariana Oncology was a radioligand therapy platform company with a diversified pipeline across multiple targets and radionuclides—recently acquired by GSK for up to $1.7B. Mariana's platform model and similar stage pre-acquisition make it a highly comparable peer, demonstrating pharma appetite for radiopharma platforms.
  • RayzeBio: RayzeBio developed actinium-225-based radiopharmaceuticals and was acquired by Bristol-Myers Squibb for $4.1B in 2024. RayzeBio's alpha-emitter focus and similar pre-commercial stage profile make it a benchmark comparable for both platform value and likely acquisition outcomes.
  • Fusion Pharmaceuticals: Fusion Pharmaceuticals developed targeted alpha therapies (TAT) using actinium-225 and was acquired by AstraZeneca for $2.4B in 2024. Fusion's alpha-emitter radiopharma platform and oncology focus directly parallel Actithera's isotope-agnostic, covalent-chemistry approach.
  • Ariceum Therapeutics: Ariceum is an emerging radiopharmaceutical biotech developing RLTs for cancer with a focus on targets including somatostatin receptors and other oncology indications. As a private, clinical-stage RLT biotech, Ariceum offers a close comparable for Actithera's development trajectory and fundraising profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Actithera social profiles

Digital presence

Actithera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Actithera leadership team

Management profile

Number of profiles

Profiles7 records

Actithera funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Actithera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Actithera

What does Actithera do?

Actithera is a discovery-stage radiopharmaceutical biotech that develops next-generation radioligand therapies (RLTs) by linking radioactive isotopes to proprietary small molecule and peptide ligands. Its lead asset is a FAP-targeting small molecule radioligand therapy in IND-enabling studies, supported by a covalent chemistry platform that prolongs tumor retention and is isotope-agnostic across alpha and beta emitters.

Is Actithera a public or private company?

Actithera is a private company. It is classified as venture growth investor backed and is currently operating.

When was Actithera founded?

Actithera was founded in 2021. It employs 11 to 50 people.

Where is Actithera based?

Actithera is headquartered in Cambridge, United States, in the North America region.

How does Actithera make money?

Two revenue lines are on record. Radiopharmaceutical Development and Commercialization is the primary driver. The others are platform Licensing and Partnerships.

Who are Actithera's main competitors?

Broad incumbents on record are Novartis, Bayer, Lantheus Holdings and Telix Pharmaceuticals. Direct peers are ITM Isotope Technologies, Philochips, Mariana Oncology, RayzeBio, Fusion Pharmaceuticals and Ariceum Therapeutics.

Does Actithera have an API?

No public API is recorded for Actithera.

What industry is Actithera in?

Actithera's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Actithera Names Steven Kelly As CEO, Briggs Morrison As Board Chair, And John Crowley As Independent DirectorActithera appointed Steven Kelly as CEO and Briggs Morrison as board chair, with John Crowley as independent director, as it prepares to advance its lead fibroblast activation protein-targeted radioligand therapy into clinical development. The company raised a $75.5 million Series A in July 2025 to fund pipeline and clinical progress.citybizActithera Names Steven Kelly CEO as Radiopharmaceutical Pipeline Nears Clinical DevelopmentActithera appointed Steven Kelly as CEO and board member to advance its lead fibroblast activation protein-targeted radioligand therapy into clinical development. The Oslo and Cambridge-based company also named Briggs Morrison chair and John Crowley an independent director. Founder Andreas Goutopoulos remains president and head of R&D.Labiotech.euWill radioligand therapies keep the momentum going in 2026?In 2025, radioligand therapy shifted from a niche oncology tool to earlier treatment lines, most notably when the FDA expanded Novartis' Pluvicto label for use in PSMA-positive metastatic castration-resistant prostate cancer before chemotherapy and Novartis reported positive phase 3 PSMAddition data in metastatic hormone-sensitive disease. Private financing for the sector surged with Nuclidium raising CHF 79 million, Actithera $75.5 million, ARTBIO $132 million, and AdvanCell $112 million to build isotope access and manufacturing infrastructure alongside clinical programs. Aktis Oncology launched 2026 with a $318 million IPO anchored by Eli Lilly, signaling sustained capital appetite for the modality as the field awaits ITM's FDA decision on Lu-edotreotide-177 in August and further data on alpha-emitting radioligands from programs like RayzeBio's RYZ101.GlobeNewswireActithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical OfficerActithera appointed Dr. Darshan Dalal as Chief Medical Officer to lead clinical strategy and build its clinical development organization. He brings over 15 years of experience advancing more than 10 radioligands, including a key role in Pluvicto's development. The appointment follows Actithera's $75.5 million Series A financing in July 2025.PharmiWeb.comActithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical OfficerActithera, a radiopharmaceutical biotech company headquartered in Oslo, Norway and Cambridge, Massachusetts, announced the appointment of Dr. Darshan Dalal as Chief Medical Officer. Dr. Dalal brings over 15 years of global oncology and hematology leadership, having advanced more than 10 radioligands from preclinical through Phase III stages and previously holding roles at AstraZeneca and Novartis, including a key role in developing Pluvicto. The appointment is intended to drive the company's lead FAP-targeting radioligand therapy into clinical development as Actithera advances its pipeline of precision-engineered radiopharmaceuticals.GlobeNewswireActithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical OfficerActithera, a radiopharmaceutical biotech company headquartered in Oslo and Cambridge, announced the appointment of Dr. Darshan Dalal as Chief Medical Officer to lead clinical strategy as its lead FAP-targeting radioligand therapy advances into the clinic. Dr. Dalal brings over 15 years of radiopharmaceutical leadership experience, having advanced more than 10 radioligands across development stages and holding key roles at AstraZeneca and Novartis, including involvement in Pluvicto. The appointment coincides with Actithera's Series A financing of $75.5 million raised in July 2025 to accelerate its pipeline development.PR NewswireActithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical ApplicationsActithera announced an exclusive license agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for two patent families covering covalent chemistry technologies developed in Professor Nir London's laboratory. The licensed technologies enable site-specific, durable, and traceless radiolabeling of tumor-specific proteins, designed to enhance tumor selectivity and retention in radiopharmaceuticals for cancer treatment. The company will integrate these innovations into its existing discovery platform as it advances its lead FAP-targeting radioligand candidate toward clinical development, supported by its recent $75.5 million Series A financing.PharmiWeb.comActithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical ApplicationsActithera has secured an exclusive license from Yeda, the Weizmann Institute's commercial arm, for covalent chemistry technologies designed to enhance targeted radiopharmaceutical therapies for cancer. The technologies, developed in Professor Nir London's lab, enable durable and site-specific radiolabeling of tumor proteins, potentially improving retention and therapeutic outcomes.Pulse 2.0Actithera: $75.5 Million Series A Secured For Advancing Radioligand TherapiesActithera closed an oversubscribed $75.5 million Series A financing round. The funds will drive clinical development of its FAP-directed radioligand therapy candidate and expand its discovery platform. The company plans to use the capital for preclinical pipeline expansion.ArcticstartupNorway & US-based Actithera raises $75.5M Series A to advance radioligand therapy pipelineNorway and US-based biotech company Actithera has closed a $75.5 million Series A financing round to support clinical development of its lead FAP-targeting radioligand therapy candidate and expand its discovery platform. The funding round was co-led by M Ventures, Hadean Ventures, Sofinnova Partners, and 4BIO Capital, with participation from five additional investors. Actithera plans to use the proceeds to initiate clinical trials and advance its pipeline of small molecule radiopharmaceuticals designed to improve tumor retention and therapeutic precision.